During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with high-risk factors. PCa screening significantly reduces PCa morbidity and mortality.
Keywords: History of prostate cancer screening; PSA; Prostate; Prostate cancer; Prostate cancer screening; Prostate cancer screening guidelines; Prostate-specific antigen; United States Preventive services Task Force.
Copyright © 2017 Elsevier Inc. All rights reserved.